Biotech Startup KaliVir Immunotherapeutics Raises $14M in Series A Extension Funding

KaliVir Immunotherapeutics, a Pittsburgh, PA-based clinical-stage biotechnology company developing multi-mechanistic oncolytic immunotherapy programs, has raised $14 million in a Series A extension funding round led by Company K Partners, bringing the total amount to $25 million.

The round also saw participation from SV Investment, Flexus Partners, as well as continued support from existing investors including affiliates of Nextrans and Quad Investment Management.

The company plans to use the proceeds to advance the clinical development of VET3-TGI, including patient enrollment in the ongoing STEALTH-001 Phase 1/1b clinical trial for patients with advanced solid tumors. The funds will also support general corporate activities.

Funding Snapshot

About KaliVir Immunotherapeutics

Founded in 2019 KaliVir Immunotherapeutics is a clinical-stage biotechnology company developing oncolytic immunotherapies for cancer treatment.

The company uses its proprietary VET™ platform and vaccinia virus technology to engineer viral therapies designed to selectively target tumor cells while activating the immune system.

Read More:California-Based RockRose Risk Raises $12.5M in Series A Funding

Its approach aims to combine direct tumor cell targeting with immune activation, and modification of the tumor microenvironment.

Core offerings include:

• Oncolytic immunotherapies
• VET™ platform
• VET3-TGI
• Tumor-targeting viral therapies
• Immune microenvironment modulation

Core Technologies / Products / Services